Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Dr. Roukos: Invited/Solicited/Commissioned Articles


EDITORIALS/REVIEWS/COMMENTARIES/CRITIQUES ONLY: Overall Impact Factor 45.869



Impact Factor
1.
Roukos DH.
Biologic genetic information predicts and may change future clinical outcomes in both at-risk hereditary cancer individuals and metastatic recurrence cancer patients
Cancer Biol Ther (in press). (Invited review).
2.981
     
2.
Roukos DH, Fatouros M, Tsianos E, Kappas AM.
Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification?
Nat Clin Pract Oncol (in press). (Invited commentary).
-
     
3.
Roukos DH and Kappas AM.
Prevention of hereditary breast ovarian cancer. Individualized approaches
Nat Clin Pract Oncol (In press). (Invited Review).
- (new)
     
4.
 Roukos DH, Liakakos T, Karatzas G, Kappas AM.
 Can VEGF-D and VEGFR-3 be used as biomarkers for  therapeutic  decisions in patients with gastric cancer?
 Nat Clin Pract Oncol. 2006 Aug;3(8):418-9. (Invited  Commentary)
- (new)
-
5.
 Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P,  Roukos DH,  Kappas AM.
 Selecting a specific pre- or postoperative adjuvant therapy  for individual patients with operable gastric  cancer.
 Expert Rev Anticancer Ther 2006 June; 6(6): 931-9.  (Invited Review)
- (new)
-
6.
 Roukos DH, Fatouros M, Paraskevaidis E, Kappas AM.
 Is an aromatase inhibitor more effective than tamoxifen in  neoadjuvant endocrine therapy for breast cancer?
 Nat Clin Pract Oncol. 2006 Feb; 3(2): 82-83.
(Invited  Commentary)
- (new)
-

7.

 Roukos DH, Kappas AM.
 Does neoadjuvant versus adjuvant systemic treatment improve  outcomes in breast cancer?
 Nat Clin Pract Oncol 2005 Jul 01; 2: 342-343. (Invited  commentary)
- (new )
     

8.

 Roukos DH, Kappas AM.
 Perspectives in the treatment of gastric cancer.
 Nat Clin Pract Oncol 2005 Feb 01; 2:98-107
(Invited Review)
- (new )
     
9.

 

 Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A,  Paraskevaidis E, Kappas AM.
 Factors increasing local recurrence in breast conserving  surgery.
 Expert Rev Anticancer Ther 2005 Aug; 5(4): 737-45  (Invited Review)
-
     
10.

 

 Agnantis NJ, Paraskevaidis E, Roukos DH.
 Preventing breast, ovarian cancer in BRCA carriers: rational of  prophylactic surgery and promises of surveillance.
 Ann Surg Oncol. 2004 Dec;11(12):1030-4. Epub 2004 Nov 15.  (Editorial).
4.035
     
11.

 

 Kappas AM, Fatouros M , Roukos DH .
 Is it time to change surgical strategy for gastric cancer in the  United States?
 Ann Surg Oncol. 2004 Aug;11(8):727-30. Epub 2004 Jul 12  (Editorial).
4.035
     

12.

 Roukos DH
 Early-stage gastric cancer: a highly treatable disease.
 Ann Surg Oncol. 2004 Feb;11(2):127-9 (Editorial).
4.035
     

13.

 Roukos DH , Kappas AM , Agnantis NJ .
 Perspectives and risks of breast-conservation therapy for breast  cancer.
 Ann Surg Oncol. 2003 Aug;10(7):718-21 (Editorial).
3.574
     

14.

3.824
     

15.

 Kappas AM , Roukos DH.
 Quality of surgery determinant for the outcome of patient with  gastric cancer.
 Ann Surg Oncol. 2002 Nov;9(9):828-30 (Editorial).
3.824
     

16.

 Roukos DH, Kappas AM .
 Targeting the optimal extent of lymph node dissection for gastric  cancer.
 J Surg Oncol.
2002 Oct;81(2):59-62; discussion 62 (Guest  Editorial).
1.502
     

17.

 Roukos DH , Kappas AM , Tsianos E .
 Role of surgery in the prophylaxis of hereditary cancer  syndromes.
 Ann Surg Oncol. 2002 Aug;9(7):607-9
(Editorial).
3.824
     

18.

 Roukos DH
 Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to  extensive surgery?
 Ann Surg Oncol. 2002 Apr;9(3):220-1 (Editorial)
.
3.824
     

19.

 Roukos DH, Kappas AM .
 Limitations in controlling risk for recurrence after curative surgery  for advanced gastric cancer are now well-explained by molecular- based mechanisms.
 Ann Surg Oncol. 2001 Sep;8(8):620-1 (Editorial).
3.308
     

20.

 Roukos DH .
 Current status and future perspectives in gastric cancer  management.
 Cancer Treat Rev. 2000 Aug;26(4):243-55
(Invited Review).
2.053
     

21.

2.8
     

22.

 Roukos DH , Kappas AM, Encke A .
 Extensive lymph-node dissection in gastric cancer: is it of  therapeutic value?
 Cancer Treat Rev.
1996 Jul;22(4):247-52 (Editorial).
2.250

Dr. Roukos INVITED ARTICLES:                   Overall Impact Factor
45.869

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 22 May 2003